{"id":5081,"date":"2023-11-06T18:31:12","date_gmt":"2023-11-06T23:31:12","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/"},"modified":"2024-12-03T14:58:30","modified_gmt":"2024-12-03T19:58:30","slug":"the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/","title":{"rendered":"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&rsquo;s disease"},"content":{"rendered":"<h2 class=\"title\">Abstract<\/h2>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p>This study investigated the molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&rsquo;s disease (AD). We analyzed A\u03b2 deposition in the temporal cortex and striatum in 116 autopsies, including Lewy body disease (LBD; N = 51), multiple system atrophy (MSA; N = 10), frontotemporal lobar degeneration-TDP-43 (FTLD-TDP; N = 16), and progressive supranuclear palsy (PSP; N = 39). The LBD group exhibited the most A\u03b2 deposition in the temporal cortex and striatum (90\/76%, respectively), followed by PSP (69\/28%), FTLD-TDP (50\/25%), and the MSA group (50\/10%). We conducted immunohistochemical analysis using antibodies targeting eight A\u03b2 epitopes in the LBD and PSP groups. Immunohistochemical findings were evaluated semi-quantitatively and quantitatively using digital pathology. Females with LBD exhibited significantly more severe A\u03b2 deposition, particularly A\u03b2<sub>42<\/sub>\u00a0and A\u03b2<sub>43<\/sub>\u00a0, along with significantly more severe tau pathology. Furthermore, a quantitative analysis of all A\u03b2 peptides in the LBD group revealed an association with the APOE-\u03b54 genotypes. No significant differences were observed between males and females in the PSP group. Finally, we compared striatal A\u03b2 deposition in cases with LBD (N = 15), AD without \u03b1-synuclein pathology (N = 6), and PSP (N = 5). There were no differences in the pan-A\u03b2 antibody (6F\/3D)-immunolabeled deposition burden among the three groups, but the deposition burden of peptides with high aggregation capacity, especially A\u03b2<sub>43<\/sub>\u00a0, was significantly higher in the AD and LBD groups than in the PSP group. Furthermore, considerable heterogeneity was observed in the composition of A\u03b2 peptides on a case-by-case basis in the AD and LBD groups, whereas it was relatively uniform in the PSP group. Cluster analysis further supported these findings. Our data suggest that the type of concomitant proteinopathies influences the spectrum of A\u03b2 deposition, impacted also by sex and APOE genotypes.<\/p>\n<\/div>\n<p><strong class=\"sub-title\">Keywords:\u00a0<\/strong>Lewy body disease; amyloid-beta; apolipoprotein E \u03b54; progressive supranuclear palsy; sex difference; striatum.<\/p>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-5081","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&#039;s disease - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&#039;s disease - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract This study investigated the molecular spectrum of amyloid-beta (A\u03b2) ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:58:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/\",\"name\":\"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer's disease - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2023-11-06T23:31:12+00:00\",\"dateModified\":\"2024-12-03T19:58:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer's disease - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/","og_locale":"fr_CA","og_type":"article","og_title":"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer's disease - CCNA - CCNV","og_description":"Abstract This study investigated the molecular spectrum of amyloid-beta (A\u03b2) ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:58:30+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/","name":"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer's disease - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2023-11-06T23:31:12+00:00","dateModified":"2024-12-03T19:58:30+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/the-molecular-spectrum-of-amyloid-beta-a%ce%b2-in-neurodegenerative-diseases-beyond-alzheimers-disease-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/5081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=5081"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=5081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}